CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP MOUTHWASH
Land: Canada
Taal: Engels
Bron: Health Canada
Productkenmerken
(SPC)
17-02-2015
Sommige documenten voor dit product zijn momenteel niet beschikbaar, u kunt een verzoek sturen naar onze klantenservice en we zullen u hiervan op de hoogte stellen zodra we ze kunnen verkrijgen.
Verzend verzoek.
Verzend verzoek.
Werkstoffen:
CHLORHEXIDINE GLUCONATE
Beschikbaar vanaf:
SAGE PRODUCTS LLC
ATC-code:
A01AB03
INN (Algemene Internationale Benaming):
CHLORHEXIDINE
Dosering:
0.12%
farmaceutische vorm:
MOUTHWASH
Samenstelling:
CHLORHEXIDINE GLUCONATE 0.12%
Toedieningsweg:
BUCCAL
Eenheden in pakket:
15ML/473ML
Prescription-type:
Prescription
Therapeutisch gebied:
MISCELLANEOUS ANTI-INFECTIVES
Product samenvatting:
Active ingredient group (AIG) number: 0107629007; AHFS:
Autorisatie-status:
CANCELLED POST MARKET
Autorisatie datum:
2022-04-22
Productkenmerken
_ _
_ _
_Page 1 of 19_
PRODUCT MONOGRAPH
CHLORHEXIDINE GLUCONATE 0.12% ORAL RINSE, USP
Chlorhexidine Gluconate 0.12% Oral Rinse
Liquid, 0.12% Chlorhexidine Gluconate
Antigingivital Oral Rinse
Sage Product LLC
3909 Three Oaks Road
Cary, IL 60013
USA
Date of Preparation:
February 17, 2015
Submission Control No: 180308
_ _
_ _
_Page 2 of 19_
TABLE OF CONTENTS
PART I: HEALTH PROFESSIONAL INFORMATION
.........................................................3
SUMMARY PRODUCT INFORMATION
........................................................................3
INDICATIONS AND CLINICAL USE
..............................................................................3
CONTRAINDICATIONS
...................................................................................................3
WARNINGS AND PRECAUTIONS
..................................................................................4
ADVERSE REACTIONS
....................................................................................................6
DOSAGE AND ADMINISTRATION
................................................................................6
OVERDOSAGE
..................................................................................................................7
ACTION AND CLINICAL PHARMACOLOGY
..............................................................8
STORAGE AND STABILITY
............................................................................................9
SPECIAL HANDLING INSTRUCTIONS
.........................................................................9
DOSAGE FORMS, COMPOSITION AND PACKAGING
.............................................10
PART II: SCIENTIFIC INFORMATION
...............................................................................11
PHARMACEUTICAL INFORMATION
..........................................................................11
CLINICAL TRIALS
..........................................................................................................12
DETAILED PHARMACOLOGY
.........................
Lees het volledige document
